Evidence map›Paper›PMID 40008877›Full record

ArticleAntimicrobial agents and chemotherapy2025

Optimizing phage therapy for carbapenem-resistant

Shi-Yong Fu, Xiu-Zhen Chen, Peng-Cheng Yi, Jie Gao, Wei-Xiao Wang, Shuang-Lin Gu, Jing-Han Gao, Du-Xian Liu, Han-Feng Xu, Yi Zeng and 3 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Shi-Yong Fu *Department of Oncology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0003-0101-4746
Xiu-Zhen Chen *Department of Tuberculosis, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Peng-Cheng YiDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Jie GaoDepartment of Oncology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Wei-Xiao WangClinical Research Center, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Shuang-Lin GuClinical Research Center, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Jing-Han GaoClinical Research Center, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Du-Xian LiuDepartment of Pathology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Han-Feng XuDepartment of Oncology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Yi ZengDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.
Chun-Mei HuDepartment of Tuberculosis, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0000-0002-3788-4191
Qin ZhengDepartment of Oncology, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0008-3260-9167
Wei ChenClinical Research Center, the Second Hospital of Nanjing, Affiliated Hospital to Nanjing University of Chinese Medicine, Nanjing, China.ORCID 0009-0006-2352-4351

Funding

MOST | National Natural Science Foundation of China (NSFC) 82272340Nanjing Municipal Health Bureau YKK22131
6 · The paper itself

Abstract

The increase in multidrug-resistant (MDR)

Indexed as

BacteremiaBacteriophagesCarbapenem-Resistant EnterobacteriaceaeCarbapenemsEnterobacter cloacaeEnterobacteriaceae InfectionsPhage TherapyAcinetobacter baumanniiAnimalsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialFemaleMiceMicrobial Sensitivity TestsAnti-Bacterial AgentsCarbapenemsdose optimizationEnterobacter cloacae complexhost rangeOmpAphage therapyprophylactic usereceptor

Identifiers

PMID40008877
PMCPMC11963603

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.